Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ramipril; Telmisartan; Valsartan

Criteria

Inclusion Criteria:

• Males or females of non-childbearing potential, 18 to 65 years of age with moderate hypertension

• Patients who are eligible and able to participate in the study

Exclusion criteria:

• Severe hypertension or secondary form of hypertension.

• Serum potassium > 5.1 mEq/L (mmol/L)

• Heart failure

• Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention

• Uncontrolled or life-threatening arrythmia

Other protocol-defined inclusion/exclusion criteria may apply